A.forall announced the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With this acquisition, A.forall extends its marketed portfolio in the US, marking a significant expansion of its US footprint and a key milestone in the company’s focus on high-quality generics worldwide.
The acquired portfolio includes four well-established hospital products that address critical therapeutic needs:
- Dihydroergotamine Mesylate (neurology – for the treatment of migraine and cluster headaches)
- Piperacillin/Tazobactam (infectious disease – broad-spectrum antibiotic for hospital-acquired infections)
- Tranexamic Acid (hematology – to control bleeding in surgical and trauma settings)
- Phenylephrine Hydrochloride (anesthesiology – to manage hypotension during surgery)
These medicines are widely integrated in US hospital protocols and marketed via established pharmaceutical distributors and group purchasing organizations, ensuring strong clinical familiarity among healthcare professionals. The newly acquired products will be commercialized through A.forall’s US subsidiary, Milla Pharmaceuticals Inc.
The two late-stage pipeline products target complementary therapeutic areas and are expected to launch in the coming years.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!